ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2668

A Randomized, Double-Blind, Dose Ranging Study Comparing FX006, An Intra-Articular (IA) Sustained-Release Formulation Of Triamcinolone Acetonide (TCA), To An Approved Injectable Suspension Of TCA In Patients With Osteoarthritis (OA) Of The Knee

Neil Bodick1, Joelle Lufkin1, Christina Willwerth1, Pierre Lachance2, Gregory Jasey3, Anil Gupta4, Anthony Chris5, Marc Russo6, Michael O'Mahony7, Sam Henein8, Louise Murdoch9, Ferdinandus de Looze10, David Hunter11 and Michael Clayman1, 1Flexion Therapeutics, Burlington, MA, 2Clinique St-Louis (Recherche) Inc, Quebec, QC, Canada, 3North Walkerville Orthopaedic Associates, Windsor, ON, Canada, 4Anil K. Gupta Medicine Professional Corporation, Toronto, ON, Canada, 5Aim Health Group, Waterloo, ON, Canada, 6Hunter Clinical Research, Broadmeadow, Australia, 7London Road Diagnostic Clinic and Medical Centre, Sarnia, ON, Canada, 8SKDS Research Inc., Newmarket, ON, Canada, 9Emeritus Research, Malvern East, Australia, 10AusTrials Pty Limited, Sherwood, Australia, 11Royal North Shore Hospital, St. Leonards, Australia

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Knee, Osteoarthritis, pain and steroids

  • Tweet
  • Email
  • Print
Session Information

Session Title: Osteoarthritis I: Therapeutics in Osteoarthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: FX006 is a novel sustained-release formulation of TCA in poly(lactic-co-glycolic) acid microspheres intended to maintain therapeutic concentrations in the joint  up to 3 months following IA injection. In patients (pts) with OA of the knee, FX006 was compared to an approved injectable suspension of TCA (TCA IR) to identify a dose of FX006 to move forward into Phase 3. 

Methods: Pts with baseline average daily pain intensity (ADP) of ≥5 to ≤9 on an 11 point Numeric Rating Scale (NRS) ranging from 0 (no pain) to 10 (pain as bad as you can imagine) were randomized (1:1:1:1) and treated with a single IA injection of FX006 (containing 10, 40 or 60 mg of TCA) or 40 mg of TCA IR.  Pts were evaluated at 7 visits over 12 wks for efficacy, safety and PK.  Primary endpoint: change from Baseline to each of Wks 8, 10 and 12 in the weekly mean of ADP.  Secondary endpoints: time to onset of pain relief, WOMAC (pain, stiffness and function), responder status, and global impression of change.

Results: Pts (228) were randomized and treated (FX006 10 mg, n=58, FX006 40 mg, n=59, FX006 60 mg, n=60; TCA IR, n=51).  Treatment arms were well balanced across demographic and baseline characteristics (mean baseline ADP: 6.5).  FX006 40 mg was superior to TCA IR on weekly mean of ADP at Wk 5 to Wk 10 (p<0.05) (average pain reduction -0.9) (Figure 1). The 40 mg dose also demonstrated significant improvement over TCA IR (p<0.05) in secondary outcomes at Wk 8 (Table 1).  Time to onset of pain relief was the same for FX006 40 mg and TCA IR.  The 10 mg dose produced effects that were consistently improved relative to TCA IR but of lessor magnitude than those of the 40 mg dose.  The 60 mg dose did not produce an improvement relative to the 40 mg dose. There were no related SAEs.  AEs were generally mild and unrelated to study drug.  Local knee-related AEs, lab assessments, ECGs and vital signs were unremarkable and similar across all treatments.  Plasma PK across the FX006 doses were linear and dose-dependent.  Peak plasma concentrations achieved with TCA IR were 10x of that seen with FX006 40 mg. 

Conclusion: In pts with OA of the knee, the 40 mg dose of FX006 demonstrated an amplified and prolonged therapeutic effect relative to TCA IR.  A Phase 3 study of the 40 mg dose of FX006 is being planned.

 


Disclosure:

N. Bodick,

Flexion Therapeutics,

1,

Flexion Therapeutics,

3;

J. Lufkin,

Flexion Therapeutics,

1,

Flexion Therapeutics,

3;

C. Willwerth,

Flexion Therapeutics,

1,

Flexion Therapeutics,

3;

P. Lachance,
None;

G. Jasey,
None;

A. Gupta,
None;

A. Chris,
None;

M. Russo,
None;

M. O’Mahony,
None;

S. Henein,
None;

L. Murdoch,
None;

F. de Looze,
None;

D. Hunter,
None;

M. Clayman,

Flexion Therapeutics,

1,

Flexion Therapeutics,

3.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-randomized-double-blind-dose-ranging-study-comparing-fx006-an-intra-articular-ia-sustained-release-formulation-of-triamcinolone-acetonide-tca-to-an-approved-injectable-suspension-of-tca-in-p/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences